Advertisement
Advertisement
GLMD
Galmed Pharmaceuticals Ltd.
0.59
USDSponsored
-0.01
-1.46%
Aug 10, 14:58 UTC -4
Closed
After-Market
0.59
0.00
-0.02%
GLMD Earnings Reports
Positive Surprise Ratio
GLMD beat 24 of 38 last estimates.
63%
Next Report
Date of Next Report
Aug 26, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.39
Implied change from Q1 26 (Revenue/ EPS)
--
/-239.29%
Implied change from Q2 25 (Revenue/ EPS)
--
/-38.10%
Galmed Pharmaceuticals Ltd. earnings per share and revenue
On Jul 08, 2026, GLMD reported earnings of 0.28 USD per share (EPS) for Q1 26, beating the estimate of -0.38 USD, resulting in a 174.82% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.39 USD, with revenue projected to reach -- USD, implying an decrease of -239.29% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
Nature's Sunshine Products Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.21
Surprise
-23.75%
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
What were Galmed Pharmaceuticals Ltd.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Galmed Pharmaceuticals Ltd. reported EPS of $0.28, beating estimates by 174.82%, and revenue of $0.00, -- -- expectations.
How did the market react to Galmed Pharmaceuticals Ltd.'s Q1 2026 earnings?
The stock price moved -- 0%, changed from $0.57 before the earnings release to $0.57 the day after.
When is Galmed Pharmaceuticals Ltd. expected to report next?
The next earning report is scheduled for Aug 26, 2026.
What are the forecasts for Galmed Pharmaceuticals Ltd.'s next earnings report?
Based on --
analysts, Galmed Pharmaceuticals Ltd. is expected to report EPS of -$0.39 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement